Protocol No
SPRINGWORKS-NIR-OGT-201
Principal Investigator
Elizabeth Hopp
Phase
II
Summary
In this study we want to find out more about an investigational drug, Nirogacestat, in people with ovarian granulosa cell tumors. The purpose of this research study is to investigate the safety
and how well nirogacestat works in participants with relapsed/refractory ovarian granulosa cell
tumors. Relapsed disease means a cancer has come back. Refractory disease means a cancer has stopped responding to treatment.
Description
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs).
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov